1 – 10 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
(
- Contribution to journal › Article
- 2024
-
Mark
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Longer Interval Between First Colonoscopy With Negative Findings for Colorectal Cancer and Repeat Colonoscopy
(
- Contribution to journal › Article
- 2023
-
Mark
External Validation of the Ovarian-Adnexal Reporting and Data System (O-RADS) Lexicon and the International Ovarian Tumor Analysis 2-Step Strategy to Stratify Ovarian Tumors Into O-RADS Risk Groups
(
- Contribution to journal › Article
- 2022
-
Mark
Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes
(
- Contribution to journal › Article
-
Mark
Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-up
(
- Contribution to journal › Article
-
Mark
Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer-Reply
(
- Contribution to journal › Letter
- 2019
-
Mark
Association of Immune Marker Changes with Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
2019) In JAMA Oncology(
- Contribution to journal › Article